Reports and resources
On this page
The Zero Childhood Cancer program is a ground-breaking program led by the Children’s Cancer Institute and the Sydney Children’s Hospitals Network as well as all major Australian childhood cancer researchers to deliver Australia’s first ever personalised medicine program for children with high-risk cancer.
By using personalised medicine and expert review panels, the Zero Childhood Cancer program or ZCC aims to treat each child’s cancer in the most targeted way possible and hopefully improve their cancer outcomes.
The success of the program is greatly improved if the recommended medicine choice can be accessed and administered as quickly as possible, however, drugs that are unapproved for a particular indication, as is the case for a significant number of ZCC requests, are more challenging to acquire.
When the program clinicians found they weren’t always able to access the medicines they sought in a timely manner, they reached out to industry better understand the issues.
Medicines Australia’s Oncology Industry Taskforce or OIT pulled together medical representatives across their member companies for an open forum with clinicians and researchers to understand how they can better enable timely access to the medicines identified by the ZCC researchers.
A report was prepared to summarise the outcomes from that workshop titled “Navigating (Compassionate) Access to Medicines For Trials” (hyperlink). The participants appreciated the candor and collaborative spirit from across all sectors represented.
This report highlights the need for increased awareness of programs such as ZCC and early engagement and collaboration between industry, trial leaders and clinicians seeking access.
- Navigating (Compassionate) Access to Medicines For Trials Learnings from Industry to aid the Zero Childhood Cancer Trial and Recommendations arising from Industry / PRISM engagement – August 2020
Reports by Michael Wonder – 2016
The Oncology Industry Taskforce commissioned Wonder Drug Consulting Pty Ltd (WDC) to prepare a report on access to new cancer medicines in Australia. WDC conducted an analysis on this issue in 2014. Timely access to new cancer medicines via the Pharmaceutical Benefits Scheme (PBS) remains an important public health care goal. The objective of the project was to update the 2014 analysis of submissions for new medicines for patients with cancer to the Pharmaceutical Benefits Advisory Committee (PBAC) and other comparable health technology assessment (HTA) agencies.
- Analysis of PBAC submissions and outcomes for medicines for patients with cancer (2010-2016) 810k
- Analysis of submissions and outcomes for medicines for patients with cancer; an international comparison (2010-2016) 925k
The 2016 reports follows on from Michael Wonder’s report, commisioned in late 2013 by the Oncology Industry Taskforce. This 2013 report comparing Australia’s access to cancer medicines to other countries entitled Reimbursement success rates and timelines for new medicines for cancer; an international comparison can be accessed here 554k
Access to Cancer Medicines 2013
This report was the first comprehensive assessment of stakeholder perspectives into access to new cancer medicines and highlights many challenges within the current system. It includes contribution from various cancer care stakeholders including health consumer organisations, clinicians, researchers, government and payers.
The report was launched at a sponsored symposium at the Medical Oncology Group of Australia’s (MOGA) Annual Scientific Meeting on 31 July 2013. The report can be accessed here 3,816k
Following the launch of the Access to Cancer Medicines in Australia report on Wednesday 31 July 2013, Medicines Australia through its Oncology Industry Taskforce invited submissions for comments/feedback on the initial findings of the Report.
One of the principal outcomes of the Report is the involvement of the wider community to participate in an informed and collaborative debate to identify how existing processes must progress to meet emerging challenges.
It is Medicine Australia’s preference that all submissions will be made publicly available on the Medicines Australia website; however Medicines Australia will keep a submission in confidence if requested.
Should you require any additional information please send an email to the Oncology Industry Taskforce
- Amgen 209k
- Anonymous letter 104k
- AstraZeneca 357k
- Bayer Australia 336k
- Bowel Cancer Australia 299k
- Brain Tumour Alliance Australia 215k
- Breast Cancer Network Australia 291k
- Bristol-Myers Squibb 61k
- Cancer Drugs Alliance 1,572k
- Cancer Voices Australia 459k
- CanSpeak 146k
- Cooperative Trials Group for Neuro Oncology (COGNO) 30k
- Consumers Health Forum of Australia 2,676k
- Fresenius Kabi Australia Pty Limited 1,319k
- Lung Foundation 789k
- Medical Oncology Group Australia (MOGA) 204k
- Melanoma Patients Australia 522k
- MSD 219k
- Novartis 319k
- Pharmacy Guild of Australia 176k
- Rare Cancers Australia 38k
- Roche 1,152k
- Sandoz 314k
- Society of Hospital Pharmacists 90k
- Sanofi 909k
- Takeda Pharmaceuticals Australia 4,833k
- Unicorn Foundation 139k